Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ana Benavides"'
Autor:
Marta Regueiro Purriños, Luis Duocastella Codina, Marc Amorós Aguilar, María López Benito, José Manuel Gonzalo Orden, Felipe Fernández Vázquez, José R. Altónaga, Isabel Perez Serranos, Claudia Pérez Martínez, Arnau Vidal Parreu, Rodrigo Estévez Loureiro, Ana Benavides Montegordo, María Molina Crisol, Carlos Cuellas Ramón, David Viñuela Baragaño, Armando Pérez de Prado, Tomás Benito González
Publikováno v:
Revista Española de Cardiología. 70:1059-1066
Resumen Introduccion y objetivos Los nuevos stents farmacoactivos (SFA), disenados para solventar las limitaciones de los existentes, han de someterse inicialmente al analisis preclinico. El objetivo es analizar la eficacia y la seguridad de nuevos S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbd2f341ce8c53a904eb23b3a1cb864a
https://doi.org/10.1016/j.recesp.2017.02.030
https://doi.org/10.1016/j.recesp.2017.02.030
Autor:
José Manuel Gonzalo Orden, Arnau Vidal Parreu, Claudia Pérez Martínez, Tomás Benito González, Carlos Cuellas Ramón, Rodrigo Estévez Loureiro, José R. Altónaga, María Molina Crisol, Isabel Perez Serranos, Marc Amorós Aguilar, Luis Duocastella Codina, David Viñuela Baragaño, Marta Regueiro Purriños, Armando Pérez de Prado, María López Benito, Ana Benavides Montegordo, Felipe Fernández Vázquez
Publikováno v:
Revista Española de Cardiología (English Edition). 70:1059-1066
New drug-eluting stents (DES) designed to overcome the limitations of existing devices should initially be tested in preclinical studies. Our objective was to analyze the safety and efficacy of new biodegradable polymer-based DES compared with bare-m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efd63fba3982d4d03b643a9f32879663
https://doi.org/10.1016/j.rec.2017.05.021
https://doi.org/10.1016/j.rec.2017.05.021
Publikováno v:
Investigational New Drugs. 12:277-281
Eleven patients with solid tumors for whom effective therapy was not available entered a phase I study of mitonafide given as a short intravenous (i.v.) infusion daily for 3 consecutive days. The initial dose level was selected according to the exper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d670b86b67ac67ba2461f161186804e
https://doi.org/10.1007/bf00873041
https://doi.org/10.1007/bf00873041
Autor:
Nuria Ribelles, Ana Benavides, Miguel Martín, Joan Carles, Agustin Barnadas, Alberto Abad, Rafael Rosell
Publikováno v:
Investigational New Drugs. 10:171-175
Mitonafide is the lead compound of a new series of antitumor drugs, the 3-Nitronaphthalimides, which have shown antineoplastic activity in vitro as well as in vivo. This phase I Mitonafide study in non-small cell lung cancer using a 120-hour continuo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f13ddcf8960095481a59b4b0393181a
https://doi.org/10.1007/bf00877242
https://doi.org/10.1007/bf00877242
Autor:
Vicente Guillem, Andres Poveda, Manuel Llombart, Erich Schlick, Ana Benavides, Cristóbal Gaspar, Miguel Martín, Virtudes Soriano, Miguel Muñoz, Amparo Ruiz, Ernesto Forner, Teresa Olmos, Carlos Fernández-Martos
Publikováno v:
Investigational New Drugs. 10:177-181
Mitonafide was the first synthetized compound of a new series of 3-nitronaphthalimides with intercalative properties. A phase I study with a conventional escalation scheme was developed. The schedule of drug administration was a daily x 5 days by sho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be8d2bf5fe26728794a2695c5a4332e
https://doi.org/10.1007/bf00877243
https://doi.org/10.1007/bf00877243
Autor:
Eduard Serra, Aurora Sánchez, María Asunción López-Ariztegui, Feliciano J. Ramos, Gabriel Capellá, Juana Fernández-Rodríguez, Belén Canet, Ignacio Blanco, Ana Benavides, Llúcia Benito, Eva Pros, Conxi Lázaro
Publikováno v:
Human mutation. 30(3)
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder affecting 1:3,500 individuals. Disease expression is highly variable and complications are diverse. However, currently there is no specific treatment for the disease. NF1 is caused by m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18995c7d7b034a32c9e970e46126a072
https://pubmed.ncbi.nlm.nih.gov/19241459
https://pubmed.ncbi.nlm.nih.gov/19241459
Autor:
Cristina Grávalos, Albert Abad, Miguel Martín, Xavier Fabregat, Albert Font, Francisco Molina, María Teresa Díaz-Puente, Ana Benavides
Publikováno v:
Investigational new drugs. 14(2)
This study investigated the antitumoral activity in colorectal cancer and toxicity of a 5-day continuous infusion of a new cytostatic agent, Mitonafide, that had previously shown to be neurotoxic when administered as a short daily x 5 days infusion.S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::534857f6dba7783be3f4199c5046f89c
https://pubmed.ncbi.nlm.nih.gov/8913845
https://pubmed.ncbi.nlm.nih.gov/8913845